Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
- 19 septembre 2024 - 1 mn de lecture
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.
19 septembre 2024
1 mn de lecture
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic...
19 septembre 2024
1 mn de lecture
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
19 septembre 2024
1 mn de lecture
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
19 septembre 2024
1 mn de lecture
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
19 septembre 2024
1 mn de lecture
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
19 septembre 2024
1 mn de lecture
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
19 septembre 2024
1 mn de lecture
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
19 septembre 2024
1 mn de lecture
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
19 septembre 2024
1 mn de lecture
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
19 septembre 2024
1 mn de lecture